BioCardia (BCDA) Capital Expenditures (2010 - 2026)

BioCardia (BCDA) has reported Capital Expenditures for 12 consecutive years, with $3000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $3000.0 in Q1 2026; TTM through Jun 2026 was $9000.0, a 125.0% increase from a year earlier, with the FY2025 full-year figure at $7000.0, up 16.67% from the prior year.
• Capital Expenditures was $3000.0 for Q1 2026 at BioCardia, down from $6000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $29000.0 in Q1 2022 and troughed at $1000.0 in Q4 2024.
• A 5-year average of $8166.7 and a median of $3000.0 in 2024 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures sank 95.12% in 2022 and jumped 500.0% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $2000.0 in 2022, then changed by 0.0% to $2000.0 in 2023, then slumped by 50.0% to $1000.0 in 2024, then jumped by 500.0% to $6000.0 in 2025, then slumped by 50.0% to $3000.0 in 2026.
• The last three Capital Expenditures figures came in at $3000.0 (Q1 2026), $6000.0 (Q4 2025), and $1000.0 (Q2 2025), per Business Quant data.